Multiple analysts initiated Buy ratings on Lineage, citing its strong acquisition track record and technological investments. Analysts project high single-digit growth in AFFO and EBITDA for Lineage ...
Ratings for Lineage Cell Therapeutics (AMEX:LCTX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of ...
Lineage, the largest temperature-controlled warehouse REIT, is trading near all-time lows since 2024's IPO due to industry headwinds and recent guidance cuts. LINE maintains a solid 5.3% dividend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results